London, United Kingdom – Bionical Ltd. T/A Bionical Emas, the first and only full-service Clinical research Organization combining Clinical Development, Early Access Programs and Clinical Trial Supply, is proud to announce the opening of a new office in Oxford, England.
The Oxford office is to be led and managed by Peter Embley, SVP Pharmacovigilance, Regulatory & Health Economic Science. Peter stated, “The Hub expresses our intent to be amongst our clients and stakeholders, in one of Europe’s key science technology and business environments, to better understand their requirements and provide a customized, solution-based service’. He added ‘The launch coincides with our new service, Bionical Emas Consults. BEC is a range of flexible consultancy services, from strategic regulatory advice to pharmacovigilance, pricing & reimbursement roadmaps, to strategic partnership solutions.”
Danny Nasmyth-Miller, Executive Vice President Clinical Development at Bionical Emas, shared his thoughts about the latest addition to the growing Bionical Emas group: “We are proud to provide our customers with office-based staff across the UK and Europe. The Oxford office enables us to enact upon our desire to directly contribute to the development of innovative new medicines, technologies and devices at source. As we continue to rapidly expand, we look to build our global presence in strategic locations, to support our desire to be recognized as the leading global specialist CRO.”
For more information about Bionical Emas, please contact email@example.com.
Bionical Emas is the only CRO to combine Clinical Development, Early Access Programs and Clinical Trial Supply, to deliver a unique, seamless approach bringing new medicines to patients faster. Through our dedication and commitment to our customers we can provide unique, integrated services, shaped to fit any clinical need, ultimately accelerating the drug development process and providing earlier access to medicine for patients.
Bionical Emas bring decades of experience developing and commercializing medicines at global, regional, and national levels. We provide full service, end-to-end support to drive pharmaceutical and biotech product development from first-in-human to the end of the product lifecycle.
The Bionical Emas team is your ideal strategic, regulatory, consultancy partner. Providing a range of services, from ad-hoc, specific regulatory, technical or therapeutic advice, to comprehensive, full-service provisions. We provide a range of drug development solutions for our clients, including; Regulatory Services, Quality Assurance, Data Management, Pharmacovigilance, Clinical Operations and Early Access Programs.Explore